You just read:

PDS Biotechnology Corp. Announces Clinical Collaboration with Merck to Evaluate Combination of Versamune® PDS0101 and KEYTRUDA® (pembrolizumab) for Metastatic Head and Neck Cancer

News provided by

PDS Biotechnology Corporation

Jul 10, 2017, 07:00 ET